Published 2 years ago

FDA Panel Finds Duvelisib Risks Outweigh Benefits in CLL/SLL

Summary by Ground News

FDA issued a warning in late June that the PI3 kinase (PI3K) inhibitor may increase the risk of death and serious side effects. The FDA's Oncologic Drugs Advisory Committee (ODAC) reviewed the record for duvelisib for this indication. Of the 12 panelists, eight voted "no" and four voted "yes"

0 Articles

All

Left

Center

Right

Medscape

FDA Panel Finds Duvelisib Risks Outweigh Benefits in CLL/SLL

An expert panel questioned the value of the FDA-approved drug following 5-year follow-up data that showed a possible increased risk of death among patients with relapsed or refractory CLL/SLL.

2 years ago·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.